Video

GenesisCare administers novel diagnostic agent Pylarify to first US patient

This video features commentary from Leonard Bitterman, the first patient in the United States to receive Pylarify (piflufolastat F 18), a novel radioactive diagnostic agent indicated for PSMA-PET imaging of lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and men with suspected recurrence based on an elevated PSA level. Brief commentary is also provided by Kishore K. Dass, MD, a radiation oncologist at GenesisCare in Boca Raton, Florida, where Bitterman received the treatment.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content
© 2025 MJH Life Sciences

All rights reserved.